Best in Biotech 7 Aug 2024
Top biotech books of all time
Here are 51 great biotech books for this summer 2024 that are bound to get you hooked. From sci-fi to the nitty-gritties of biotech, we’ve got you covered!
- Latest Posts
In Depth 6 Aug 2024
The biggest private biotech investments in July 2024
The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024.
Best in Biotech 2 Aug 2024
Six epigenetics companies making strides in 2024
In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry.
Podcast 2 Aug 2024
Rebroadcast: How does AI assist drug discovery?
Listen to our podcast to discover how AI is revolutionizing drug discovery by tackling “undruggable” targets like KRAS.
News and Trends 1 Aug 2024
European regulators reject Alzheimer’s drug Leqembi: is it downhill from here?
European regulators have now refused to market the Alzheimer’s drug Leqembi after it was approved by the FDA last year.
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
ADVERTISEMENT
ADVERTISEMENT
In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
News and Trends 29 Jul 2024
Influenza solution deals pile up as pandemic preparedness increases
Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics.
Podcast 26 Jul 2024
The first mass-market cell therapy?
Listen to our conversation with CEO Greg Kunst about how Aurion’s treatment could be the first mass-market cell therapy available
More News! 26 Jul 2024
Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies
Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round.
In Depth 25 Jul 2024
The future of inflammatory bowel disease treatment: what is on the horizon?
Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.
In Depth 24 Jul 2024
Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?
Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
ADVERTISEMENT
